Datwyler (Middletown, Delaware), a leading provider of high-value, system-critical elastomer components, announced a collaboration with LTS Device Technologies, a developer of smart wearable devices for drug delivery, and Stevanato Group, a leading global provider of drug containment, drug delivery, and diagnostic solutions.

Together, the companies aim to broaden the scope of large-volume subcutaneous drug delivery by enabling convenient on-body administration of larger volumes – meeting the evolving needs of patients, alongside market demands. The three companies will unveil their platform solution at a joint Learning Lab presentation: When Size Matters: The Evolution of Self-Delivery Solutions for Subcutaneous Administration at Pharmapack, Jan 21-22, 2026, in Paris, France.

Supporting Patient-Centric Healthcare for Large-Volume Self-Administration
The pharmaceutical landscape for subcutaneous drug delivery is undergoing rapid transformation, driven by the increasing use of biologics and other sensitive therapeutics in clinical practice. According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, as small molecule research and development productivity declines.

At the same time, patient preferences are changing. A recent Mayo Clinic study (Mayo Clinic's) found that 73 per cent of participants favoured in-home self-administration after 24 weeks of therapy – underscoring the need for solutions that support decentralised, convenient patient-centric healthcare versus hospitals or other medical settings.  

"By enabling patients to self-administer therapies at home, subcutaneous drug administration facilitates a growing shift towards more accessible personalised healthcare. Datwyler's spray-coated NeoFlex plungers increase the functional reliability of large volume injection systems and promote greater comfort and safety for the patients," said Paolo Ferrigno, Product Manager, PFS & Cartridges, Datwyler.